FDA declines to approve Cingulate’s ADHD treatment over manufacturing issues 

 ADHD in the News 2026-06-04


June 2 (Reuters) - Drug developer Cingulate (CING.O), opens new tab said on ​Tuesday the U.S. Food and Drug Administration declined to approve its ‌treatment for attention deficit hyperactivity disorder, citing manufacturing-related concerns. In its complete response letter, the FDA did not flag any concerns about the drug's safety or effectiveness, Cingulate said.

View Article: Reuters, June 2, 2026




Other Articles in this Edition

SMFM Reaffirms Acetaminophen as First-Line Medication for Treating Pain and Fever During Pregnancy

We analysed 14 million Reddit posts to reveal a striking shift in how we talk about mental health 

FDA declines to approve Cingulate’s ADHD treatment over manufacturing issues 

Acceptance and Commitment Therapy helps parents of children with disabilities

ADHD Linked to Greater Reproductive Health Challenges

Adults with ADHD may pay high price to mask traits and fit in, SFU study finds

When “Too Much” Becomes Your Story

Focus apps are failing neurodivergent minds, new research finds 

The beginning of a long journey: Integrating lived experience into the design of an app for young people with ADHD

1 in 5 teens turn to AI chatbots for mental health advice, but a majority of them keep it secret

More than half of adults with ADHD in clinical settings have a co-occurring personality disorder

Amid School Techlash, Accessibility Advocates Worry About Exclusion 

Prescription Drug Monitoring Programs Shape Care. Our Patients Should Know. (Opinion)